Last Updated on July 1, 2026 by The Health Master
Form 483
The United States Food and Drug Administration (USFDA) has issued a Form 483 to Dr. Reddy’s Laboratories following an intensive inspection of one of their manufacturing facilities in India.
USFDA Inspection at the Dr. Reddy’s Hyderabad
The USFDA recently completed a thorough inspection of the biologics manufacturing facility of Dr. Reddy’s in Hyderabad, India.
According to the official statement released by Dr. Reddy’s on the Bombay Stock Exchange (BSE), the USFDA investigators spent over a week evaluating the manufacturing facility.
The inspection started on June 16 and ended on the 25th of June.
The USFDA inspectors presented a Form 483 to the company with seven observations that the investigators made while at the facility.
While the company confirmed the receipt of the Form 483, they did not disclose the specific nature of the seven observations that were made by the United States regulatory authorities.
What is a USFDA Form 483?
A Form 483 is sent to the management of the manufacturing facility after the USFDA investigators note any potential violations of the Federal Drug Act and related acts.
USFDA Form 483 Definition:
A Form 483 is issued to the management of the firm after observing any compliance issues during the inspection.
These findings are published in writing to inform the firm of the areas in which it failed to adhere to current Good Manufacturing Practices (cGMP).
Following the completion of the inspection, the company must present a detailed plan to resolve these issues.
Dr. Reddy’s has committed to addressing all the issues mentioned in the USFDA Form 483 by the stipulated time to avoid any further actions being taken against them by the United States regulatory body.
Recent USFDA Inspections of the Hyderabad Plant
This inspection is but one of the USFDA inspections of the Dr. Reddy’s facility in Hyderabad.
The facility has been inspected by USFDA officials for several years in a row.
-
Dr. Reddy’s plant in Hyderabad was inspected by USFDA officials in October 2023.
-
In September 2025, five manufacturing compliance deficiencies were noted at the facility, resulting in the presentation of a Form 483 to Dr. Reddy’s.
-
June 2026 saw the inspection of the same facility by the USFDA inspectors with seven observations of potential manufacturing and compliance issues.
The repetition of these inspections and findings indicates the challenges faced by pharmaceutical manufacturers in maintaining the compliance regulations on a daily basis in their international manufacturing facilities.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
USFDA issued Form 483 to Lupin with 4 observations: Pune
USFDA issued Form 483 to Lupin with 6 observations: Nagpur
USFDA issued Form 483 to Reddy’s with 5 observations: Hyderabad
USFDA issued Form 483 to Biocon with 5 observations
USFDA issued Form 483 to Aurobindo with 8 observations
USFDA issued Form 483 to Alembic Pharma with 1 observation
USFDA issued Form 483 with two observations to Aurobindo for API plant
Drug alert: 94 drug samples declared as NSQ in August 2025
USFDA issued Form 483 to Lupin with 6 observations: Nagpur
Haryana: ₹5,000 Crore investment Plan for Pharma and Medical Device
CDSCO Redefines Cocrystals as ‘New Drugs’
NPPA fixed retail price of 9 formulations: September 2025
USFDA issued Form 483 to Reddy’s with 5 observations: Hyderabad
USFDA approval granted for blood clotting drug: Alembic
USFDA puts import Alert on Sun Pharma: Halol
Indian Drug Regulation Goes 97% Digital: CDSCO
5 Northern State SDCs Unite Against Counterfeit Drugs
